4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl)isoindoline-1,3-dione

4-amino-2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl)isoindoline-1,3-dione, commonly known as E7820, is a small molecule inhibitor that targets angiogenesis, the process of forming new blood vessels. It is being developed as a potential anti-cancer drug by Eisai Co., Ltd. E7820 works by inhibiting the activity of several proteins involved in angiogenesis, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). By blocking these proteins, E7820 prevents the formation of new blood vessels, which can limit the growth and spread of tumors. In preclinical studies, E7820 has shown promising anti-tumor activity in a variety of cancer types, including lung, breast, and pancreatic cancer. Clinical trials are currently underway to evaluate the safety and efficacy of E7820 in cancer patients. Chemically, E7820 is a complex molecule with a molecular weight of 533.65 g/mol. It contains multiple functional groups, including an amine group, a sulfonyl group, and a lactam ring. Its structure and properties make it a challenging molecule to synthesize, but also provide opportunities for further optimization and development.